AstraZeneca Pharma India Limited — Important, 15-04-2025: Updates

AstraZeneca Pharma India Limited has surrendered the marketing authorization for Olaparib film-coated tablets (100mg and 150mg) indicated for use in combination with Abiraterone and Prednisone for the treatment of metastatic castration-resistant prostate cancer. The company confirms that it has not marketed this indication in India since receiving the authorization on November 17, 2023. The decision to discontinue is attributed solely to commercial reasons and not related to the drug's safety or efficacy. AstraZeneca continues to maintain all other existing permissions for Olaparib in India, indicating ongoing commitment to its portfolio despite this withdrawal. Investors should note this development as a refinement of the company's strategy in the oncology segment.